Zoetis Inc.
Zoetis Announces $2.0 Billion Convertible Senior Notes Offering
Summary
Zoetis Inc. completed a private offering of $2.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2029. The net proceeds are estimated at $1.9696 billion after deducting discounts and expenses. Zoetis intends to use these proceeds for capped call transactions, stock repurchases, and other corporate purposes. The Notes, issued under an indenture with Deutsche Bank Trust Company Americas as trustee, can be converted into Zoetis common stock under certain conditions. Zoetis also entered into capped call transactions to hedge against potential dilution from the conversion of the Notes.
Get alerts for ZTS
Be first to know when Zoetis Inc. files with the SEC.
Filing Categories
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Official SEC Documents